Other Events ·
Replimune Group, Inc. held its annual meeting of stockholders on September 15, 2026, where shareholders approved an…
REPLReplimune Group, Inc.
Replimune Group, Inc. held its annual meeting of stockholders on September 15, 2026, where shareholders approved an amendment to increase the authorized number of common shares from 150 million to 300 million. The Company filed a Certificate of Amendment with the Delaware Secretary of State on that date, making the change effective immediately. Additionally, stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027, and approved a non-binding advisory resolution on executive compensation. The company operates in the biotechnology industry, focusing on the development of immunotherapies for cancer.